Therapeutic Use of MicroRNAs in Lung Cancer

Table 2

Strategies for in vivo miRNA delivery.

	Type of particles	Advantages	Disadvantages	Reference
Synthetic	Mimic inhibitor	Safe and simple; Easy to produce; Low immunogenicity	Poor cellular uptake; Rapid degradation and clearance	[94]
Neutral lipoplexes/liposomes	MaxSuppressor; SLNs; SMARTICLES; siPORT	Low immunogenicity; Lung accumulation; Easy to produce; Available commercially	Nonspecific uptake; Low transfection efficiency; Cytotoxicity	[79, 80, 84, 86]
Cationic lipoplexes/liposomes	PU-PEI; DOTMA	Low immunogenicity; Easy to produce; High cellular uptake	Cytotoxicity; Tend to form aggregates; Moderate transfection efficiency; Nonbiodegradability	[81, 83]
Viral vectors	Adenovirus; Lentivirus	High transfection efficiency; Stable expression	Difficult to produce; High immunogenicity; High toxicity	[33, 43]